NCT00128180View on ClinicalTrials.gov

Efficacy of Methylprednisolone for Hantavirus Cardiopulmonary Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

December 31, 2010

Study Completion Date

October 31, 2011

Conditions
Hantavirus Infections
Interventions
DRUG

Methylprednisolone

Intravenous methylprednisolone 16 mg/kg/day for 3 days as follows: 8 mg/kg (up to 500 mg) given over first hour followed by 8 mg/kg over the next 23 hours; then 16 mg/kg (up to 1000 mg) on days 2 and 3 administered over 24 hours.

DRUG

Placebo

Placebo

Trial Locations (1)

Unknown

Facultad de Medicina Clinica Alemana- Universidad del Desarrollo, Santiago

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

University of New Mexico

OTHER

NCT00128180 - Efficacy of Methylprednisolone for Hantavirus Cardiopulmonary Syndrome | Biotech Hunter | Biotech Hunter